AJRCCM百年纪念:肺癌格局的变迁——过去、现在与未来
本文回顾了过去100年肺癌从罕见报告疾病转变为全球男女癌症死亡首因的历史变迁,归因于烟草消费增加及随之而来的控烟公共卫生努力。尽管多数肺癌仍晚期诊断,但在高危吸烟者筛查、诊断手段和化学预防方面已有显著进展;手术与放疗的改进提升了对早期疾病的管理能力,尤其是对不适合传统开放切除的患者。过去十年靶向治疗和免疫治疗的发展堪称最显著的进步。文章还展望了分子与影像学新方法在肺癌预防、早筛和治疗中的转化前景。
要点
- 肺癌从罕见病变为全球癌症死亡首因,烟草消费增加是核心驱动因素。
- 多数肺癌仍晚期诊断,但高危吸烟者筛查、诊断与化学预防已有显著进展。
- 靶向与免疫治疗是近十年最突出的治疗进步,早期疾病手术与放疗也在改进。
核心结论
- 过去100年肺癌从罕见报告疾病转变为全球男女癌症死亡首因,烟草消费增加是主要驱动因素。
- 尽管多数肺癌仍晚期诊断,筛查、诊断、化学预防及治疗方面已有显著进展。
- 靶向与免疫治疗是近十年最突出的治疗进步,分子与影像学新方法有望进一步改变肺癌防控格局。
研究设计与样本
- 本文为综述,回顾过去100年肺癌领域的主要变迁。
主要发现
- 肺癌已成为全球男女癌症死亡的首要原因。
- 多数肺癌仍在晚期才被诊断。
- 在高危吸烟者筛查、诊断模式和化学预防方面已有显著进展。
- 手术与放疗的改进提升了对早期疾病的管理能力,尤其对不适合传统开放切除的患者。
- 过去十年靶向治疗和免疫治疗的发展是最显著的治疗进步。
临床怎么用
- 关注高危吸烟者筛查以促进早期发现。
- 对不适合传统开放切除的早期患者可考虑改进的手术或放疗方式。
- 靶向与免疫治疗已成为肺癌治疗的重要组成部分。
局限性
- 本文为历史回顾性综述,未报告原始研究数据或定量合并结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The past century has witnessed a transformative shift in lung cancer from a rare reportable disease to the leading cause of cancer death among men and women worldwide. This historic shift reflects the increase in tobacco consumption worldwide, spurring public health efforts over the past several decades directed at tobacco cessation and control. Although most lung cancers are still diagnosed at a late stage, there have been significant advances in screening high-risk smokers, diagnostic modalities, and chemopreventive approaches. Improvements in surgery and radiation are advancing our ability to manage early-stage disease, particularly among patients considered unfit for traditional open resection. Arguably, the most dramatic progress has occurred on the therapeutic side, with the development of targeted and immune-based therapy over the past decade. This article reviews the major shifts in the lung cancer landscape over the past 100 years. Although many ongoing clinical challenges remain, this review will also highlight emerging molecular and imaging-based approaches that represent opportunities to transform the prevention, early detection, and treatment of lung cancer in the years ahead.
引用
- Vachani A, Sequist LV, Spira A, et al. AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. Am J Respir Crit Care Med. 2017. PMID: 28459327. doi:10.1164/rccm.201702-0433CI
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。